Patients who take phosphate binders may be at a 22% higher risk of death that those who take other non-calcium based treatments.
The management of chronic kidney disease-mineral bone disorder (CKD-MBD) is central to the care of patients with kidney disease. Key to these efforts is the availability of clinically accessible biomarkers that can help distinguish between a wide variety of bone and mineral disturbances related to kidney failure.
Chitosan gum could offer dialysis patients an inexpensive way to control phosphorus nonsystemically without adding to their daily pill burden.
Declines in serum phosphorus over time may improve survival.
Worsening or resistant hyperphosphatemia may be an under-appreciated consequence of secondary hyperparathyroidism.
Calcium-based and non-calcium-based binder use were associated with similar death risks.
Levels declined significantly from 7.2 to 5.0 mg/dL, data show.
Vascular calcification contributes to increased cardiovascular risk in dialysis patients.
New findings are consistent with those from previous animal studies.
PA21 comparable in safety and efficacy to sevelamer carbonate out to 52 weeks, study finds.
Serum levels vary throughout the day, and higher phosphorus intake exaggerates the early afternoon rise in serum phosphorus.
New findings raise questions "on the generalizability of previous research studies to the clinic setting," researchers conclude.
Low phosphorus increases all-cause and cardiovascular mortality only among the elderly.
Phosphorus levels are lower in postmenopausal women on estrogen replacement therapy.
Use of the agents is associated with a 29% and 22% decreased risk of all-cause and cardiovascular mortality.
A high proportion of top-selling grocery items contain phosphorus additives, and consumption may be encouraged by their lower cost.
It significantly decreased cardiovascular and all-cause mortality compared with calcium carbonate.
The increasing popularity of processed convenience foods could be a factor.